| 0.02 0 (0%) | 04-25 14:43 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.41 | 1-year : | 0.46 |
| Resists | First : | 0.35 | Second : | 0.4 |
| Pivot price | 0.34 |
|||
| Supports | First : | 0.29 | Second : | 0.24 |
| MAs | MA(5) : | 0.33  |
MA(20) : | 0.34 |
| MA(100) : | 0.69 |
MA(250) : | 1.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 39.7 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 3.08 | Low : | 0.16 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SRNE ] has closed above bottom band by 36.4%. Bollinger Bands are 86.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.33 - 0.33 | 0.33 - 0.33 |
| Close: | 0.33 - 0.34 | 0.34 - 0.34 |
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Tue, 12 Mar 2024
Sorrento wins DoJ's venue-based challenge to bankruptcy filing (OTCMKTS:SRNEQ) - Seeking Alpha
Sat, 02 Mar 2024
Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price ... - Investors
Fri, 01 Mar 2024
Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants - Sorrento ... - Investors
Tue, 27 Feb 2024
Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal - Sorrento Therapeutics, Inc. - Investors
Wed, 21 Feb 2024
Sorrento faked venue in bankruptcy filing: Justice Department (OTCMKTS:SRNEQ) - Seeking Alpha
Sat, 18 Feb 2023
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | -0.24 |
| EPS Est This Year | -1.08 |
| EPS Est Next Year | -0.65 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.31 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 3.05 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|